ARYx Therapeutics, Inc. Stock

ARYX

US0433871094

Biotechnology & Medical Research

Market Closed - OTC Markets 16:47:07 26/06/2023 +03			5-day change	1st Jan Change
0.001200 ^USD	+1,100.00%		+119,900.00%	+119,900.00%

1 week	+119,900.00%
Current month	+119,900.00%

Valuation : ARYx Therapeutics, Inc.

Market Cap	9.03M 7.75M 7.28M 6.65M 12.55M 862M 12.61M 86.13M 33.38M 435M 33.92M 33.19M 1.44B	P/E 2008	-1.76x	P/E 2009	-2.66x
Enterprise Value	11.41M 9.79M 9.19M 8.39M 15.84M 1.09B 15.91M 109M 42.14M 549M 42.83M 41.9M 1.82B	EV / Sales 2008	4,019,605x	EV / Sales 2009	-
Free-Float	100%	Yield 2008 *	-	Yield 2009	-

* Estimated data More valuation ratios

Press Releases : ARYx Therapeutics, Inc.

10/03/11	ARYX THER : ARYx Therapeutics Informed of Additional Delay by FDA and Begins Wind-Down of Operations	BU
24/12/10	ARYX THER : ARYx Therapeutics Clarifies Current Status of Operations	BU
21/12/10	ARYX THER : ARYx Therapeutics to Transfer to the NASDAQ Capital Market	BU
16/12/10	ARYX THER : ARYx Therapeutics Provides Update on Company Status	BU
15/11/10	ARYX THER : ARYx Therapeutics Reports Third Quarter Results	BU

More press releases

ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
ARYX Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

3 years	0		0
5 years	0		0
10 years	0		0.05

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARYX THERAPEUTICS, INC.	+1,100.00%	+119,900.00%	+119,900.00%	+119,900.00%	33
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	70.42B
ARGENX SE	+0.67%	+2.08%	+48.72%	+92.42%	65.4B
BIONTECH SE	-1.31%	-0.50%	+7.41%	-4.29%	28.28B
WUXI BIOLOGICS (CAYMAN) INC.	-0.59%	+1.53%	+58.69%	+11.38%	26.57B
INSMED INCORPORATED	+0.40%	-4.80%	-5.89%	+469.55%	27.16B
GENMAB A/S	-0.16%	+0.75%	+35.92%	-17.98%	20.09B
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	20.61B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.86%	-1.31%	+13.51%	+545.40%	15.87B
EXELIXIS, INC.	-1.09%	+3.14%	+46.32%	+155.12%	13.9B
Average	+110.32%	+1.04%	+12,043.51%	+12,167.56%	28.83B
Weighted average by Cap.	+0.87%	+0.72%	+56.28%	+157.45%

	2008	2009
Net sales	19.72 16.93 15.89 14.51 27.39 1.88K 27.52 188.04 72.87 949.07 74.06 72.45 3.14K	-
Net income	-31.22M -26.79M -25.15M -22.97M -43.35M -2.98B -43.56M -298M -115M -1.5B -117M -115M -4.98B	-33.17M -28.47M -26.72M -24.4M -46.06M -3.16B -46.28M -316M -123M -1.6B -125M -122M -5.29B
Net Debt	-29.9 -25.67 -24.09 -22 -41.53 -2.85K -41.73 -285.11 -110.49 -1.44K -112.28 -109.85 -4.77K	2.37 2.04 1.91 1.74 3.29 226.14 3.31 22.6 8.76 114.09 8.9 8.71 377.87

ARYx Therapeutics, Inc. Stock

Stocks

ARYX

US0433871094

Biotechnology & Medical Research

Valuation : ARYx Therapeutics, Inc.

Press Releases : ARYx Therapeutics, Inc.

Quotes and Performance

Price Extremes

Bio Therapeutic Drugs

Financials

Company Profile

1 day	+1,100.00%
1 week	+119,900.00%
Current month	+119,900.00%
1 month	+119,900.00%
3 months	+119,900.00%
6 months	+119,900.00%
Current year	+119,900.00%